Fulgent Genetics, Inc. (Nasdaq: FLGT – Get the score) obtained a big improve briefly curiosity throughout the month of January. As of January 15, there was quick curiosity totaling 1,170,000 shares, a rise of 14.7% from the December 31 whole of 1,020,000 shares. Primarily based on common each day buying and selling quantity, of 274,400 shares, the quick rate of interest is presently 4.3 days. At present, 6.3% of the corporate’s shares are bought quick.
Analyst score adjustments
→ The following huge disaster is right here (from Porter and Firm)
Many analysis firms have commented on FLGT. Raymond James started protection of inventory of Fulgent Genetics in a analysis observe on Friday, November 18th. They issued a “Excellent” score and a worth goal of $45.00 for the corporate. Piper Sandler downgraded inventory of Fulgent Genetics from an “chubby” score to a “impartial” score and lowered the corporate’s worth goal from $65.00 to $40.00 in a analysis report on Thursday, December eighth. Credit score Suisse reduce its worth goal for shares of Fulgent Genetics from $65.00 to $50.00 and assigned an “outperform” score to the corporate in a analysis report on Monday, November 14th. lastly, StockNews.com Protection of shares of Fulgent Genetics started in a analysis report on Wednesday, October twelfth. They put a “maintain” score on the corporate. Two analysis analysts have rated the inventory with a maintain score and two of them have issued a purchase score to the inventory. Primarily based on MarketBeat knowledge, Fulgent Genetics presently has a consensus score of “Reasonable Purchase” and a consensus worth goal of $45.00.
Fulgent Genetics fill up 4.4%
Fulgent inventory genetics It opened at $34.76 on Friday. Fulgent Genetics has a twelve-month low of $28.53 and a twelve-month excessive of $73.47. The corporate has a 50-day transferring common of $32.89 and a 200-day transferring common of $40.61. The corporate has a market capitalization of $1.02 billion, a price-to-earnings ratio of 4.00 and a beta of 1.55.
Fulgent Genetics (Nasdaq: FLGT – Get the score) final launched its earnings outcomes on Monday, November seventh. The corporate reported earnings of $0.11 per share for the quarter, beating analyst estimates of ($0.02) by $0.13. The corporate had income of $105.66 million for the quarter, in comparison with consensus estimates of $103.70 million. Fulgent Genetics’ web revenue margin was 33.82% and return on fairness was 22.10%. Fairness analysts count on Fulgent Genetics to report 4.93 earnings per share for the present fiscal yr.
Institutional inflows and outflows
A number of institutional traders and hedge funds have just lately been shopping for and promoting FLGT shares. The Public Sector Pension Funding Board elevated its stake in Fulgent Genetics by 0.8% within the second quarter. The Public Sector Retirement Funding Board now owns 36,491 shares of the corporate’s inventory valued at $1,990,000 after buying a further 301 shares final quarter. SummerHaven Funding Administration LLC elevated its stake in Fulgent Genetics by 2.3% within the fourth quarter. SummerHaven Funding Administration LLC now owns 13,581 shares of the corporate’s inventory valued at $404,000 after buying a further 304 shares final quarter. The Texas Everlasting Faculty Fund elevated its stake in Fulgent Genetics by 2.4% within the third quarter. The Texas Everlasting Faculty Fund now owns 14,587 shares of the corporate’s inventory price $556,000 after buying a further 339 shares final quarter. Geneos Wealth Administration Inc elevated its stake in Fulgent Genetics by 416.8% within the first quarter. Geneos Wealth Administration Inc. Now 491 shares of the corporate’s inventory are price $30,000 after shopping for a further 396 shares final quarter. Lastly, Covington Capital Administration elevated its stake in Fulgent Genetics by 133.3% within the third quarter. Covington Capital Administration now owns 700 shares of the corporate’s inventory, valued at $27,000, after buying a further 400 shares final quarter. 43.22% of the shares are owned by funding establishments.
Fulgent Genetics Firm Profile
Fulgent Genetics, Inc. is a know-how firm engaged in offering gene testing and sequencing options. Presents genes and panels, recognized mutations, hereditary most cancers, provider screening, and tumor diagnostics options. The corporate was included on Might 13, 2016 and is headquartered in Temple Metropolis, California.
Learn extra
This immediate information alert was created by MarketBeat’s narrative science and monetary knowledge know-how to offer readers with the quickest, most correct reporting doable. This story was reviewed by the MarketBeat editorial group previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you think about Fulgent Genetics, you may need to hear this.
MarketBeat tracks Wall Road’s top-rated and top-performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized a 5 shares That prime analysts are quietly inquisitive about their purchasers to purchase now earlier than the broader market catches on…and Fulgent Genetics wasn’t even on the checklist.
Whereas Fulgent Genetics presently has a “average purchase” score amongst analysts, the higher-rated analysts suppose these 5 shares are a greater purchase.
